Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancy
Safety and Tolerability
Pharmacokinetics
Pharmacodynamics
Tumour Response
Advanced or Metastatic Breast Cancer
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
PIK3CA
AKT1
PTEN
ER Positive
HER2 Positive

Interventions

DRUG: AZD5363
DRUG: AZD5363
DRUG: AZD5363
DRUG: AZD5363

Sponsor

AstraZeneca